Erythromycin: (Average) Inhibitors of the hepatic CYP4501A2, similar to erythromycin, could inhibit the hepatic oxidative metabolism of caffeine. No specific administration is advisable besides in patients who complain of caffeine associated uncomfortable side effects. In such patients, the dosage of caffeine containing medications or the ingestion of caffeine containing products may should be diminished.
Ponatinib: (Major) Avoid coadministration of ponatinib and ketoconazole due to the potential for increased ponatinib exposure. If concurrent use cannot be avoided, scale back the ponatinib dose to the following decrease dose level (45 mg to 30 mg; 30 mg to 15 mg; 15 mg to 10 mg). If the patient is taking ponatinib 10 mg as soon as daily prior to concurrent use, avoid the use of ketoconazole and consider alternative therapy. After ketoconazole has been discontinued for 3 to 5 half-lives, resume the dose of ponatinib that was tolerated prior to beginning ketoconazole. Ponatinib is a CYP3A4 substrate; ketoconazole is a powerful CYP3A4 inhibitor. Coadministration with ketoconazole elevated the ponatinib AUC by 78%.
Betamethasone: (Average) Quinolones have been related to an elevated danger of tendon rupture requiring surgical restore or buy dihydrocodeine online uk resulting in prolonged incapacity; this risk is further elevated in those receiving concomitant corticosteroids. Discontinue quinolone therapy at the first sign of tendon inflammation or tendon ache, as these are signs that will precede rupture of the tendon.
